{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T16:37:58Z","timestamp":1794242278823,"version":"4.9.0"},"reference-count":66,"publisher":"BMJ","issue":"6","license":[{"start":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:00:00Z","timestamp":1750982400000},"content-version":"unspecified","delay-in-days":26,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"the Scientific Research Special Project of the National TCM Inheritance and Innovation Center of Henan Provincial Health Commission","award":["2023ZXZX1093"],"award-info":[{"award-number":["2023ZXZX1093"]}]},{"name":"Zhongyuan Talent Project (Yucai series), specifically the Zhongyuan Leading Talent Program (designated as Zhongyuan Famous Doctor\uff09","award":["ZYYCYU202012119"],"award-info":[{"award-number":["ZYYCYU202012119"]}]},{"name":"the Scientific Research Special Project of Traditional Chinese Medicine in Henan Province","award":["2024ZY2004"],"award-info":[{"award-number":["2024ZY2004"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,5,30]]},"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Low-level viremia (LLV) is a risk factor affecting the prognosis of patients with chronic hepatitis B (CHB). The objective of this study was to systematically assess the prevalence of LLV, thereby providing robust evidence-based medical insights into effective clinical interventions and preventative measures against LLV.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Systematic review and meta-analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data sources<\/jats:title>\n                    <jats:p>A comprehensive literature search was conducted across various databases, including China National Knowledge Infrastructure, Wanfang Data (Wanfang), China Science And Technology Journal Database (VIP-CSTJ), China Biology Medicine disc (CBMdisc), PubMed, Embase, Web of Science and the Cochrane Library, spanning from the inception of these databases up to 5 January 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Eligibility criteria<\/jats:title>\n                    <jats:p>The research type included either a cross-sectional study or a cohort study focusing on the Chinese population, with the outcome being LLV. The languages were limited to both Chinese and English. Studies with any of the following were excluded: subjects with other comorbidities, original articles inaccessible or data unavailable, and duplicate publications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data extraction and synthesis<\/jats:title>\n                    <jats:p>Literature management used EndNote X9.1, and an information extraction table was created using Microsoft Excel to record research information, including first author, year of publication and study type. The prevalence of LLV was assessed via meta-analysis. Meta-analyses were conducted in RStudio using the \u2018metaprop ()\u2019 function. Subgroup analysis and sensitivity analysis were used to identify sources of heterogeneity, and funnel plots and AS-Thompson tests were employed to evaluate publication bias.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>18 studies, encompassing a total sample of 9773 patients, were included in the analysis. Of these, 3336 patients were identified with LLV. The meta-analysis revealed that the prevalence of LLV among treated CHB patients stands at 33.6% (95% CI 30.2 to 37.0). The antigen status, antiviral treatment regimen (type of drugs and nucleos(t)ide analogues (NAs)), treatment duration, medication adherence and baseline hepatitis B virus DNA levels all affected the prevalence of LLV. Sensitivity analysis further corroborated the stability of these meta-analysis findings. The funnel plot and AS-Thompson test indicated no significant publication bias (t = \u22120.01, p=0.995).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The prevalence of LLV among CHB patients was established at 33.7% (95% CI 29.8% to 37.6%). Thus, it is imperative for clinical decision-makers to consider the various influencing factors of LLV when formulating treatment plans in order to mitigate any potential adverse outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-088756","type":"journal-article","created":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T14:45:21Z","timestamp":1751035521000},"page":"e088756","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Prevalence of low-level viremia in the treatment of chronic hepatitis B in China: a systematic review and meta-analysis"],"prefix":"10.1136","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2326-4952","authenticated-orcid":false,"given":"Lu","family":"Xie","sequence":"first","affiliation":[{"name":"The First Affiliated Hospital of Henan University of CM, Zhengzhou, Henan, China"},{"name":"Henan University of Chinese Medicine, Zhengzhou, Henan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangwei","family":"Liu","sequence":"additional","affiliation":[{"name":"Metabolism Treatment Center, Longhua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Liu","sequence":"additional","affiliation":[{"name":"Henan University of Chinese Medicine, Zhengzhou, Henan, China"},{"name":"Department of Acquired Immune Deficiency Syndrome Treatment and Research Center, The First Affiliated Hospital of Henan University of CM, Zhengzhou, Henan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengyu","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Acquired Immune Deficiency Syndrome Treatment and Research Center, The First Affiliated Hospital of Henan University of CM, Zhengzhou, Henan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijun","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Acquired Immune Deficiency Syndrome Treatment and Research Center, The First Affiliated Hospital of Henan University of CM, Zhengzhou, Henan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,6,27]]},"reference":[{"key":"2025121511561684000_15.6.e088756.1","unstructured":"World Health Organization(WHO) . Hepatitis B.Fact sheets.(2024-4-9)[2024-10-29]."},{"key":"2025121511561684000_15.6.e088756.2","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1186\/s12879-019-4428-y","article-title":"Hepatitis B infection in the general population of China: a systematic review and meta-analysis","volume":"19","author":"Wang","year":"2019","journal-title":"BMC Infect Dis"},{"key":"2025121511561684000_15.6.e088756.3","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1111\/apt.15725","article-title":"Moderate levels of serum hepatitis B virus DNA are associated with the highest risk of hepatocellular carcinoma in chronic hepatitis B patients","volume":"51","author":"Kim","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"2025121511561684000_15.6.e088756.4","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28280"},{"key":"2025121511561684000_15.6.e088756.5","first-page":"3","article-title":"Guidelines for the prevention and treatment of chronic hepatitis B (2022 version)","volume":"41","year":"2023","journal-title":"Chin J Hepatol"},{"key":"2025121511561684000_15.6.e088756.6","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29800"},{"key":"2025121511561684000_15.6.e088756.7","doi-asserted-by":"crossref","first-page":"666","DOI":"10.3748\/wjg.v27.i8.666","article-title":"New therapeutic options for persistent low-level viremia in patients with chronic hepatitis B virus infection: Increase of entecavir dosage","volume":"27","author":"Yin","year":"2021","journal-title":"World J Gastroenterol"},{"key":"2025121511561684000_15.6.e088756.8","first-page":"1268","article-title":"Current status of the research on low-level viremia in chronic hepatitis B patients receiving nucleos(t)ide analogues","volume":"37","author":"Lu","year":"2021","journal-title":"J Clin Hepatol"},{"key":"2025121511561684000_15.6.e088756.9","doi-asserted-by":"crossref","first-page":"326","DOI":"10.4274\/balkanmedj.2017.0888","article-title":"Diagnostic Dilemma for Low Viremia with Significant Fibrosis; is Hepatitis B Virus DNA Threshold Level a Good Indicator for Predicting Liver Damage?","volume":"35","author":"Yenilmez","year":"2018","journal-title":"Balkan Med J"},{"key":"2025121511561684000_15.6.e088756.10","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1016\/j.cgh.2020.03.001","article-title":"Persistent Low Level of Hepatitis B Virus Promotes Fibrosis Progression During Therapy","volume":"18","author":"Sun","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025121511561684000_15.6.e088756.11","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.14309\/ajg.0000000000002181","article-title":"Low Level of Hepatitis B Viremia Compared With Undetectable Viremia Increases the Risk of Hepatocellular Carcinoma in Patients With Untreated Compensated Cirrhosis","volume":"118","author":"Yang","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"2025121511561684000_15.6.e088756.12","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1186\/s12885-021-08483-3","article-title":"Correlation between low-level viremia and hepatitis B-related hepatocellular carcinoma and recurrence: a retrospective study","volume":"21","author":"Sun","year":"2021","journal-title":"BMC Cancer"},{"key":"2025121511561684000_15.6.e088756.13","first-page":"911","article-title":"Construction of Clinical Evidence Grading System of TCM Intervention Based on Evidence-based Medicine Principles","volume":"43","author":"Liu","year":"2023","journal-title":"Chin J Integr Tradit West Med"},{"key":"2025121511561684000_15.6.e088756.14","first-page":"525","article-title":"Analysis of peripheral blood lymphocyte status in low-level-viremia patients with chronic hepatitis B virus infection after nucleos(t)ide analogue treatment","volume":"43","author":"Guo","year":"2023","journal-title":"Zhuang Hua Wei Sheng Wu Xue and Mian Yi Xue Za Zhi"},{"key":"2025121511561684000_15.6.e088756.15","first-page":"320","article-title":"Influencing factors of low-level viremia in patients with chronic hepatitis B treated with Entecavir","volume":"28","author":"Huang","year":"2023","journal-title":"Chin Hepatol"},{"key":"2025121511561684000_15.6.e088756.16","first-page":"297","article-title":"Meta-analysis series IV: a quality assessment tool for observational studies","volume":"4","author":"Zeng","year":"2012","journal-title":"Chin J Evid Based Cardiovasc Med"},{"key":"2025121511561684000_15.6.e088756.17","unstructured":"Zhang YR . Profile of Low Level Viremia in Patients with Chronic Hepatitis B. Fujian Medical University; 2021. doi:10.27020\/d.cnki.gfjyu.2021.000464"},{"key":"2025121511561684000_15.6.e088756.18","unstructured":"Yang XF , Xu Y , Zhang BT , et al . Analysis of clinical characteristics and risk factors of low level viremia in patients withchronic hepatitis B after treatment. 2023;32:276\u201381. doi:10.3969\/j.issn.1006-5709.2023.03.008"},{"key":"2025121511561684000_15.6.e088756.19","first-page":"2252","article-title":"Influencing factors for low - level viremia in patients with chronic hepatitis B or hepatitis B liver cirrhosis and its association with the progression of liver inflammation and liver fibrosis","volume":"38","author":"Xuan","year":"2022","journal-title":"J Clin Hepatol"},{"key":"2025121511561684000_15.6.e088756.20","unstructured":"Li GH , Sun L . Risk factors of low level viremia in chronic hepatitis B treated with nucleosides (acids). Med Health 2023;4."},{"key":"2025121511561684000_15.6.e088756.21","first-page":"52","article-title":"Analysis of influencing factors of low level viremia in patients with chronic hepatitis B and cirrhosis","volume":"12","author":"Qi","year":"2022","journal-title":"J Front Med"},{"key":"2025121511561684000_15.6.e088756.22","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jhep.2023.02.038","article-title":"Demographic characteristics and associated influencing factors in treated patients with chronic hepatitis B with hypoviremia: a single-center retrospective cross-sectional study","volume":"31","author":"Li","year":"2023","journal-title":"Chin J Hepatol"},{"key":"2025121511561684000_15.6.e088756.23","first-page":"2716","article-title":"Influencing factors for low-level viremia and their dynamic changes in patients with chronic hepatitis B treated with nucleos(t)ide analogues for the first time","volume":"38","author":"Cheng","year":"2022","journal-title":"J Clin Hepatol"},{"key":"2025121511561684000_15.6.e088756.24","first-page":"556","article-title":"Influencing factors for low-level viremia in chronic hepatitis B patients treated with long-term entecavir antiviral therapy","volume":"37","author":"Chen","year":"2021","journal-title":"J Clin Hepatol"},{"key":"2025121511561684000_15.6.e088756.25","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/jgh.16357","article-title":"Risk factors of low\u2010level viremia in chronic hepatitis B patients receiving Entecavir monotherapy: a retrospective cohort study","volume":"39","author":"Chen","year":"2024","journal-title":"J of Gastro and Hepatol"},{"key":"2025121511561684000_15.6.e088756.26","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2023.1151899","article-title":"Factors associated with persistent positive in HBV DNA level in patients with chronic Hepatitis B receiving entecavir treatment","volume":"13","author":"Li","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"key":"2025121511561684000_15.6.e088756.27","doi-asserted-by":"crossref","first-page":"53","DOI":"10.5152\/tjg.2023.21978","article-title":"Prevalence and Associated Factors of Low-Level Viremia in Chronic Hepatitis B Patients After Long-Term Therapy with Nucleos(t)ide Analogs","volume":"34","author":"Han","year":"2023","journal-title":"Turk J Gastroenterol"},{"key":"2025121511561684000_15.6.e088756.28","first-page":"41","article-title":"Clinical observation of viremia after antiviral therapy with nucleot(s)ide analogues in HBV-infected patients","volume":"32","author":"Zeng","year":"2022","journal-title":"Chin J Integr Tradit West Med Liver Dis"},{"key":"2025121511561684000_15.6.e088756.29","first-page":"850","article-title":"Chronic Hepatitis B Infection with Low Level Viremia Correlates with the Progression of the Liver Disease","volume":"9","author":"Zhang","year":"2021","journal-title":"J Clin Transl Hepatol"},{"key":"2025121511561684000_15.6.e088756.30","unstructured":"Li MW . Serum HBV DNA and hepatitis B surface antigen levels help predict diseases progression in patients with low hepatitis B virus loads. Zhejiang University, 2014."},{"key":"2025121511561684000_15.6.e088756.31","first-page":"118","article-title":"Analysis of efficacy and factors influencing sequential combination therapy with tenofovir alafenamide fumarate after treatment with entecavir in chronic hepatitis B patients with low-level viremia","volume":"31","author":"Liu","year":"2023","journal-title":"Chin J Hepatol"},{"key":"2025121511561684000_15.6.e088756.32","unstructured":"Sheng MJ . A retrospective cohort study of low level viremia and progression of liver hardness in patients with chronic hepatitis B. Dali University, 2022."},{"key":"2025121511561684000_15.6.e088756.33","unstructured":"Higgins JPT , Thomas J , Chandler J , et al . Cochrane handbook for systematic reviews of interventions version 6.5 (Updated August 2024) . Cochrane, 2024. Available: www.training.cochrane.org\/handbook"},{"key":"2025121511561684000_15.6.e088756.34","doi-asserted-by":"crossref","first-page":"364","DOI":"10.3350\/cmh.2020.0012","article-title":"Low-level viremia and cirrhotic complications in patients with chronic hepatitis B according to adherence to entecavir","volume":"26","author":"Lee","year":"2020","journal-title":"Clin Mol Hepatol"},{"key":"2025121511561684000_15.6.e088756.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.11.039"},{"key":"2025121511561684000_15.6.e088756.36","first-page":"111","article-title":"Performance verification and clinical evaluation of HBV DNA high-sensitivity detection kit","volume":"11","author":"Yu","year":"2019","journal-title":"J Mol Diagn Ther"},{"key":"2025121511561684000_15.6.e088756.37","first-page":"925","article-title":"Analysis of the correlation between HBV DNA load level and hepatitis B hepatocellular carcinoma indicators and the effect on the outcome","volume":"33","author":"Xie","year":"2023","journal-title":"Chin J Integr Tradit West Med Liver Dis"},{"key":"2025121511561684000_15.6.e088756.38","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.antiviral.2016.10.011","article-title":"Role of HBsAg decline in patients with chronic hepatitis B HBeAg-negative and E genotype treated with pegylated-interferon","volume":"136","author":"Boglione","year":"2016","journal-title":"Antiviral Res"},{"key":"2025121511561684000_15.6.e088756.39","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1002\/jmv.21778","article-title":"Prediction of the response to peg-interferon-alfa in patients with HBeAg positive chronic hepatitis B using decline of HBV DNA during treatment","volume":"82","author":"Hansen","year":"2010","journal-title":"J Med Virol"},{"key":"2025121511561684000_15.6.e088756.40","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1111\/jvh.13591","article-title":"Hepatitis B e antigen loss in adults and children with chronic hepatitis B living in North America: A prospective cohort study","volume":"28","author":"Lee","year":"2021","journal-title":"J Viral Hepat"},{"key":"2025121511561684000_15.6.e088756.41","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1053\/j.gastro.2018.11.037","article-title":"New and Old Biomarkers for Diagnosis and Management of Chronic Hepatitis B Virus Infection","volume":"156","author":"Coffin","year":"2019","journal-title":"Gastroenterology"},{"key":"2025121511561684000_15.6.e088756.42","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ijid.2017.06.016","article-title":"A scoring model predicts hepatitis B e antigen seroconversion in chronic hepatitis B patients treated with nucleos(t)ide analogs: real-world clinical practice","volume":"62","author":"Geng","year":"2017","journal-title":"Int J Infect Dis"},{"key":"2025121511561684000_15.6.e088756.43","doi-asserted-by":"crossref","first-page":"443","DOI":"10.7754\/Clin.Lab.2017.170916","article-title":"Quantitative Hepatitis B e Antigen: A Better Predictor of Hepatitis B Virus DNA than Quantitative Hepatitis B Surface Antigen","volume":"64","author":"Hudu","year":"2018","journal-title":"Clin Lab"},{"key":"2025121511561684000_15.6.e088756.44","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2021.01.019"},{"key":"2025121511561684000_15.6.e088756.45","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2017-314904"},{"key":"2025121511561684000_15.6.e088756.46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.021"},{"key":"2025121511561684000_15.6.e088756.47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.12.004"},{"key":"2025121511561684000_15.6.e088756.48","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2023.02.032"},{"key":"2025121511561684000_15.6.e088756.49","doi-asserted-by":"crossref","first-page":"S844","DOI":"10.1016\/S0168-8278(22)01984-5","article-title":"Combination therapy in HBeAg-negative chronic hepatitis B patients with low-level viremia to nucleos (tide) analogues","volume":"77","author":"Chen","year":"2022","journal-title":"J Hepatol"},{"key":"2025121511561684000_15.6.e088756.50","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.3390\/v15051111","article-title":"Hepatitis B Core Antibody Level: A Surrogate Marker for Host Antiviral Immunity in Chronic Hepatitis B Virus Infections","volume":"15","author":"Shi","year":"2023","journal-title":"Viruses"},{"key":"2025121511561684000_15.6.e088756.51","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2021.105146","article-title":"Baseline serum hepatitis B core antibody level predicts HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B after antiviral treatment","volume":"193","author":"Zhao","year":"2021","journal-title":"Antiviral Res"},{"key":"2025121511561684000_15.6.e088756.52","doi-asserted-by":"crossref","DOI":"10.3390\/v16071121","article-title":"Quantitative HBV Core Antibodies as a Prognostic Marker for HBeAg Seroclearance: A Systematic Review with Meta-Analysis","volume":"16","author":"Lazarevic","year":"2024","journal-title":"Viruses"},{"key":"2025121511561684000_15.6.e088756.53","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1111\/jgh.15881","article-title":"Serum qAnti\u2010HBc combined with ALT and HBsAg predicts significant hepatic inflammation in HBeAg\u2010positive immune active patients","volume":"37","author":"Wang","year":"2022","journal-title":"J Gastroenterol Hepatol"},{"key":"2025121511561684000_15.6.e088756.54","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.1002\/jmv.27779","article-title":"Dose\u2013response relationship between qAnti\u2010HBc and liver inflammation in chronic hepatitis B with normal or mildly elevated alanine transaminase based on liver biopsy","volume":"94","author":"Zhang","year":"2022","journal-title":"J Med Virol"},{"key":"2025121511561684000_15.6.e088756.55","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1159\/000533515","article-title":"IP10 and Anti-HBc can Predict Virological Relapse and HBsAg Loss in Chronic Hepatitis B Patients after Nucleos(t)ide Analog Discontinuation","volume":"41","author":"Xie","year":"2023","journal-title":"Dig Dis"},{"key":"2025121511561684000_15.6.e088756.56","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.dld.2017.12.028","article-title":"A novel noninvasive index for the prediction of moderate to severe fibrosis in chronic hepatitis B patients","volume":"50","author":"Li","year":"2018","journal-title":"Dig Liver Dis"},{"key":"2025121511561684000_15.6.e088756.57","doi-asserted-by":"crossref","first-page":"18035","DOI":"10.1038\/nrdp.2018.35","article-title":"Hepatitis B virus infection","volume":"4","author":"Yuen","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"2025121511561684000_15.6.e088756.58","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2016.7"},{"key":"2025121511561684000_15.6.e088756.59","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2015.06.008"},{"key":"2025121511561684000_15.6.e088756.60","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/jvh.13817","article-title":"Research progress on detection methods for hepatitis B virus covalently closed circular DNA","volume":"30","author":"Sun","year":"2023","journal-title":"J Viral Hepat"},{"key":"2025121511561684000_15.6.e088756.61","doi-asserted-by":"crossref","first-page":"168","DOI":"10.5858\/arpa.2020-0112-RA","article-title":"Current Status of Clinical Application of Point-of-Care Testing","volume":"145","author":"Park","year":"2021","journal-title":"Arch Pathol Lab Med"},{"key":"2025121511561684000_15.6.e088756.62","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/jgh3.12950","article-title":"Switching from entecavir to tenofovir alafenamide for maintaining complete virological response in chronic hepatitis B","volume":"7","author":"Ishido","year":"2023","journal-title":"JGH Open"},{"key":"2025121511561684000_15.6.e088756.63","doi-asserted-by":"crossref","first-page":"23","DOI":"10.4103\/sjg.sjg_170_23","article-title":"Long-term health and economic benefits of switching to tenofovir alafenamide versus continuing on entecavir in chronic hepatitis B patients with low-level viremia in Saudi Arabia","volume":"30","author":"Sanai","year":"2024","journal-title":"Saudi J Gastroenterol"},{"key":"2025121511561684000_15.6.e088756.64","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s12876-020-01219-w","article-title":"Adherence in chronic hepatitis B: associations between medication possession ratio and adverse viral outcomes","volume":"20","author":"Allard","year":"2020","journal-title":"BMC Gastroenterol"},{"key":"2025121511561684000_15.6.e088756.65","doi-asserted-by":"publisher","DOI":"10.1038\/s41395-018-0093-9"},{"key":"2025121511561684000_15.6.e088756.66","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/jvh.13275","article-title":"Optimal drug administration manner would rescue partial virological response in chronic hepatitis B patients with entecavir or tenofovir treatment","volume":"27","author":"Tao","year":"2020","journal-title":"J Viral Hepat"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-088756","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T19:56:31Z","timestamp":1765828591000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-088756"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":66,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6,27]]},"published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1136\/bmjopen-2024-088756"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-088756","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1136\/bmjopen-2024-088756.supp9","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1136\/bmjopen-2024-088756.supp1","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1136\/bmjopen-2024-088756.supp2","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1136\/bmjopen-2024-088756.supp3","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1136\/bmjopen-2024-088756.supp4","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1136\/bmjopen-2024-088756.supp5","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1136\/bmjopen-2024-088756.supp6","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1136\/bmjopen-2024-088756.supp7","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1136\/bmjopen-2024-088756.supp8","asserted-by":"subject"}]},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6]]}}}